Returning guest, Dr. Steve Marcus, CEO of Cantex Pharmaceuticals, a clinical-stage pharmaceutical company focused on developing transformative therapies for cancer and other life-threatening medical conditions for which new treatments are urgently needed discusses Azeliragon and the launch of investigator-led clinical studies focusing on a combination with radiosurgery in patients with brain metastases, front-line treatment for glioblastoma, metastatic pancreatic cancer and treatment of patients hospitalized with COVID-19 and pneumonia to prevent acute kidney injury.

#CantexPharmaceuticals

STEPHEN G. MARCUS, M.D., CHIEF EXECUTIVE OFFICER    Stephen G. Marcus, M.D. is a physician who has focused his professional career on the development of new treatments for cancer and other life-threatening and disabling diseases. Born and educated in New York City, Dr. Marcus received his medical degree from New York Medical College. After an internal medicine residency at Lenox Hill Hospital in New York, and oncology specialty training at the University of California in San Francisco, Dr. Marcus spent several years practicing emergency and critical care medicine and medical oncology.

In 1985, Dr. Marcus entered the biotechnology industry where he has been directly responsible or played a critical role in the development of a number of important new medications. Dr. Marcus was the leader of the team of scientists and physicians who developed Betaseron as the first effective treatment of multiple sclerosis. This revolutionized the treatment of multiple sclerosis and was the forerunner of the many drugs for multiple sclerosis that are available today. Dr. Marcus played a key role in the development of fludarabine for a chronic lymphocytic leukemia, and served as the leader of multinational teams of researchers developing new treatments of cancer, multiple sclerosis, as well as other life-threatening or disabling conditions.